Nelson, Van Denburg & Campbell Wealth Management Group, LLC Ironwood Pharmaceuticals Inc Transaction History

Nelson, Van Denburg & Campbell Wealth Management Group, LLC

$2.42 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$8.32 - $15.45 $216 - $401	26 New	26 $0
Q2 2022 Aug 10, 2022	SELL	$11.05 - $12.72 $439,557 - $505,988	-39,779 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$10.61 - $12.88 $80,010 - $97,128	-7,541 Reduced 15.94%	39,779 $500,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $13.95 $57,623 - $74,018	5,306 Added 12.63%	47,320 $551,000
Q3 2021 Nov 02, 2021	BUY	$11.92 - $13.92 $23,780 - $27,770	1,995 Added 4.99%	42,014 $548,000
Q2 2021 Jul 27, 2021	BUY	$10.16 - $13.11 $75,935 - $97,984	7,474 Added 22.97%	40,019 $515,000
Q1 2021 May 11, 2021	SELL	$9.04 - $11.86 $677 - $889	-75 Reduced 0.23%	32,545 $363,000
Q4 2020 Feb 09, 2021	BUY	$9.05 - $12.2 $96,292 - $129,807	10,640 Added 48.41%	32,620 $371,000
Q3 2020 Oct 20, 2020	BUY	$8.99 - $10.74 $12,316 - $14,713	1,370 Added 6.65%	21,980 $197,000
Q2 2020 Jul 02, 2020	BUY	$9.14 - $11.97 $32,904 - $43,092	3,600 Added 21.16%	20,610 $212,000
Q1 2020 Apr 01, 2020	BUY	$8.58 - $14.01 $145,945 - $238,310	17,010 New	17,010 $171,000

Others Institutions Holding IRWD

# of Institutions

238

Shares Held

162M

Call Options Held

11.2M

Put Options Held

9.1K

Black Rock Inc. New York, NY

22.9M
Shares

$79.2 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

22M
Shares

$76.3 Million
0.0% of portfolio
Sarissa Capital Management LP Greenwich, CT

16.4M
Shares

$56.7 Million
16.75% of portfolio
Pacer Advisors, Inc. Malvern, PA

11.3M
Shares

$39 Million
0.11% of portfolio
State Street Corp Boston, MA

9.92M
Shares

$34.3 Million
0.0% of portfolio

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $530M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nelson, Van Denburg & Campbell Wealth Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nelson, Van Denburg & Campbell Wealth Management Group, LLC with notifications on news.

Account